RePOWER (SPIMM-300)

A Prospective, Non-Interventional Study of Patients with Primary Mitochondrial Myopathy (PMM)

Stealth BIOTHERAPEUTICS

RePOWER Background

- RePOWER is a prospective, non-interventional study. This means no investigational treatment will be given.
- Patients will be asked to complete a questionnaire about their current symptoms, quality of life and perform certain functional assessments, including a test called the 6-Minute Walk Test (6MWT). Participation in the trial will require the ability to walk.
- The trial is now enrolling 300 patients, aged 16-80, across North America, Europe and Australia.
- Patients must enroll in RePOWER (SPIMM-300) to participate in MMPOWER-3 (SPIMM-301). MMPOWER-3 is an interventional trial to evaluate elamipretide for the treatment of patients with PMM.

RePOWER Inclusion Criteria

- Are between 16 years to 80 years of age
- Are able to walk
- Are willing to review and able to sign the informed consent form prior to any trial-related steps
- Have never been exposed to the investigational drug elamipretide
- Have one of the following:
  - Clinical presentation of PMM, such as exercise intolerance, fatigue and/or muscle weakness
  - Physical exam findings of myopathy

For a list of trial sites, detailed enrollment criteria or additional information, please visit ClinicalTrials.gov, MitoAction.org, UMDF.org or MitochondrialDiseases.org.